Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Design of Novel Acute Myeloid Leukemia Therapeutic Targeting of CNOT3

EF 2022-23

Résumé
Acute myeloid leukemia (AML) is an aggressive type of blood cancer characterized by accumulation of immature blood cells. Chemotherapy has remained the standard of care for AML since the 1970s yet 5-year survival rates are <35% in young adults and <15% in adults above 60 years. While understanding the genetic basis of AML has led to major progress in treatment of the disease, it is now recognized that additional processes including RNA modifications and protein synthesis are also required for cancer development. Studies from our laboratory uncovered a critical role of an RNA deadenylation complex, which controls RNA metabolism and protein synthesis, in development of AML. These studies supported CNOT3, a subunit of the RNA deadenylation complex, as a potential therapeutic target for AML. CNOT3 protein levels were found elevated in AML cell lines and supported their survival. To translate this knowledge to clinical applications, the objective of my project is to develop a treatment approach that reduces CNOT3 protein levels to specifically eliminate AML cells. We will apply proteolysis-targeting chimera (PROTAC) technology, which uses a fusion molecule to recruit protein degradation machinery to a specific protein target in the cell. This technique will be used to design and implement a CNOT3-specific targeted protein degradation method. The ultimate goal of this research is to provide an effective alternative to chemotherapy for AML patients in hopes to improve the current devastating survival rates.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486293
Name
Gomes Renessa
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Design of Novel Acute Myeloid Leukemia Therapeutic Targeting of CNOT3
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Cnot3; Deadenylation; Degradation Tag; Proteolysis Targeting Chimeric; Targeted Protein Degradation; Therapeutic Design
Abstract
Acute myeloid leukemia (AML) is an aggressive type of blood cancer characterized by accumulation of immature blood cells. Chemotherapy has remained the standard of care for AML since the 1970s yet 5-year survival rates are <35% in young adults and <15% in adults above 60 years. While understanding the genetic basis of AML has led to major progress in treatment of the disease, it is now recognized that additional processes including RNA modifications and protein synthesis are also required for cancer development. Studies from our laboratory uncovered a critical role of an RNA deadenylation complex, which controls RNA metabolism and protein synthesis, in development of AML. These studies supported CNOT3, a subunit of the RNA deadenylation complex, as a potential therapeutic target for AML. CNOT3 protein levels were found elevated in AML cell lines and supported their survival. To translate this knowledge to clinical applications, the objective of my project is to develop a treatment approach that reduces CNOT3 protein levels to specifically eliminate AML cells. We will apply proteolysis-targeting chimera (PROTAC) technology, which uses a fusion molecule to recruit protein degradation machinery to a specific protein target in the cell. This technique will be used to design and implement a CNOT3-specific targeted protein degradation method. The ultimate goal of this research is to provide an effective alternative to chemotherapy for AML patients in hopes to improve the current devastating survival rates.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gomes, Renessa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~